Enhanced Omicron subvariant cross-neutralization efficacy of a monovalent SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigen
H. Y. Seo, H. Jung, H. Woo, H.-G. Jung, Y. Bak, S.-Y. Lee, Y.-M. Son, G. Yoon, Y.-M. Son, S.-Y. Hwang, I. Park, J.-S. Shin, J.-W. Oh
This study develops a modified SARS-CoV-2 spike antigen that enhances cross-neutralization against Omicron subvariants, despite reduced neutralizing potency.
bioRxiv · Sep 10, 2023 · PreprintImmunology